Material and methods S2
Experimental details, characterization data and copies of spectra Chromaster 5430) equipped with a Phenomenex Luna C-18(2) column, 10 µm, 250 × 4.6 mm, with precolumn at 1.4 mL/min flow rate were used. Freeze-drying: The product was dissolved in water and frozen with dry ice. The freeze-drying was carried out at least for 48 h at −50 °C using the instrument 5Pascal Lio5P DGT.
Biological assays
Solid phase receptor binding assays temperature. The cells were washed with PBS and the mean fluorescence intensity was measured for 10.000 gated events. The data were analyzed using flow cytometry and associated software (BD Biosciences) ( Figure S1 ). 
Cell culture
All cell culture reagents were purchased at PAN-Biotech Cell therapy and viability assay 
Competition experiment of compounds 10 and 11
The competition experiments were performed in U87-MG and MDA-MB 468 cell lines according to the following procedure: 2 × 10 3 cells/well were plated in 96-well black clear bottom plates (Perkin Elmer) and incubated overnight. A solution containing 1 × 10 −4 M of the conjugates 10 or 11 and 5 × 10 −3 M of cilengitide (50-fold excess of ligand in comparison to the conjugate) was prepared in the growth medium and 1:5 serial dilutions were prepared in cell culture media. The compounds were added to cell culture and incubated for 96 h. The starting concentration of the compounds in the wells was 0.01 mM whereas that of cilengitide was 0.5 mM. The cell viability was determined with the CellTiterGlo 2.0 assay (Promega) in accordance to manufacturer's instructions and the viability was calculated in relation to the non-treated controls for each cell line. All samples were measured in triplicate. Data analysis was carried out using software GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA).
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Synthesis of cyclo[DKP-RGD]-α-amanitin conjugates 7 and 9
Synthesis of cyclo[DKP-RGD]-uncleavable-α-amanitin (7) Scheme S1. Synthesis of cyclo[DKP-RGD]-uncleavable-α-amanitin (7). Reagents and conditions: a) glutaric anhydride, DMAP, iPr 2 NEt, DMF, overnight, yield.: 77%; b) 1. DIC, N-hydroxysuccinimide, DMF, overnight, 2. NH 2 CH 2 -cyclo[DKP-RGD] (2), PBS/MeCN (pH 7.5), overnight, yield.: 46%.
Hemiglutarate-aminohexyl-α-amanitin (15)
Compound 12a (5 mg, 4.4 μmol, 1 equiv) was dissolved in 10 µL of DMF and cooled at 0 ºC under nitrogen conditions. Glutaric anhydride (1.26 mg, 11 μmol, 2.5 equiv), DMAP (0.13 mg, 1.1 μmol, 0.25 equiv) and iPr 2 NEt (2.87 µL, 16.5 μmol, 3.75 equiv) were added as stock solutions in DMF and the reaction was stirred at 0 ºC for a few minutes. The mixture was then warmed to room temperature and stirred overnight under nitrogen atmosphere. 86, 174.17, 173.79, 173.27, 171.88, 171.65, 170.91, 170.17, 168.65, 168.53, 157.00, 139.14, 127.40, 122.47, 121.38, 114.35, 111.87, 96.07, 72.73, 69.84, 68.81, 63.36, 62.08, 59.91, 56.63, 55.73, 52.89, 51.60, 50.64, 42.58, 41.68, 39.12, 37.87, 37.21, 34.85, 33.30, 32.69, 28.06, 25.44, 25.33, 24.76, 20.76, 14.12, 12.96, 9.80 
Cyclo[DKP-RGD]-uncleavable-α-amanitin (7)
Compound 15 (7.58 mg, 6.7 μmol, 1 equiv) was dissolved in 175 µL of DMF and cooled at 0 ºC under a nitrogen atmosphere. N-hydroxysuccinimide (1.15 mg, 10 μmol, 1.5 equiv) and DIC (1.55 µL, 10 μmol, 1.5 equiv) were added as stock solutions in DMF and the reaction mixture was stirred at 0 ºC for a few minutes. The reaction was allowed to reach room temperature and stirred overnight under a nitrogen atmosphere. Volatiles were then removed in vacuo to give a solid, which was redissolved in acetonitrile (176 µL) and cooled to 0 ºC. 
Hemiglutarate-Val-Ala-α-amanitin (16)
Compound 12b (5 mg, 3.9 μmol, 1 equiv) was cooled to 0 ºC under a nitrogen atmosphere.
Glutaric anhydride (0.65 mg, 5.7 μmol, 1.5 equiv), DMAP (0.12 mg, 0.9 μmol, 0.25 equiv) and iPr 2 NEt (1 µL, 5.7 μmol, 1.5 equiv) were added as stock solutions in DMF and the reaction was stirred at 0 ºC for a few minutes. Then the mixture was warmed to room temperature and stirred overnight under a nitrogen atmosphere. 
Cyclo[DKP-RGD]-Val-Ala-α-amanitin (9)
Compound 16 (8.46 mg, 6.5 μmol, 1 equiv) was dissolved in 80 µL of DMF and cooled at 0 ºC under nitrogen conditions. N-Hydroxysuccinimide (1.11 mg, 9.7 μmol, 1.5 equiv) and DIC (1.5 µL, 9.7 μmol, 1.5 equiv) were added (the two incorporated reagents were prepared as stock solutions in DMF) and the reaction was stirred at 0 ºC for a few minutes. Then the mixture was warmed to room temperature and stirred overnight under a nitrogen atmosphere. Volatiles were then removed in vacuo to give a solid, which was re-dissolved in PBS (210 µL, pH 7.5) and 
Glutarate NHS ester-aminohexyl-α-amanitin (13a)
S12
Compound 12a (11 mg, 10.9 µmol, 1 equiv) was dissolved in 150 µL of dry DMF under nitrogen atmosphere. The solution was cooled to 0 °C, then di-N-succinimidyl glutarate (4 mg, 12 µmol. 1.1 equiv) and DIPEA (2 µL, 12 µmol, 1.1 equiv) were added and the mixture was stirred at room temperature for 6 hours. The reaction was monitored by TLC (CHCl 3 /MeOH/water 65:25:4, cinnamaldehyde staining). The crude was poured into 10 mL precooled MTBE placed in a 10 mL centrifugal tube (the reaction flask was rinsed with 3 × 50 µL of DMF and each rinsing solution was transferred to the MTBE tube). The tube was sealed, vortexed and placed in ice for 10 min. The tube was spun for 3 min at 4500 RPM in a precooled centrifuge. The supernatant was transferred to a 50 mL flask. The pellet was suspended again into 10 mL of MTBE by vortexing and sonication. The tube was placed in ice for 10 mins and the centrifugation was repeated, then the pellet was dried in vacuo. The combined MTBE phases were concentrated under reduced pressure and checked for remaining product by TLC and HPLC. The dried pellet was used in the next step without further purification (12 mg, 90% yield).
Cyclo[DKP-isoDGR]-uncleavable-α-amanitin (8)
A solution of 4 (5.0 mg, 5.8 µmol, 1 equiv) in 150 µL of PBS was added to a solution of 13a (12 mg, 10 µmol, 1.7 equiv) in 150 µL of DMF at 0 °C. The pH was adjusted to 7.3-7.6 by adding small aliquots of aqueous NaOH (0.2 M) during the first hours of reaction, until a stable value was observed, and then the reaction mixture was stirred overnight at room temperature.
The solution was directly filtered into a 3 mL vial and purified by preparative HPLC (gradient: from 95% (H 2 O + 0.05% CF 3 COOH)/5% CH 3 CN to 60% (H 2 O + 0.05% CF 3 COOH)/40% CH 3 CN in 14.5 mins), t R (product): 8.8 min. The purified product was freeze-dried to give the final product as a white solid (4.5 mg, 45% yield 
Glutarate NHS ester-Val-Ala-α-amanitin (13b)
Compound 12b (10 mg, 8.3 µmol, 1 equiv) was dissolved in 150 µL of dry DMF under nitrogen atmosphere. The solution was cooled to 0 °C, then di-N-succinimidyl glutarate (3.2 mg, 9.9 µmol, 1.2 equiv) and DIPEA (1.6 µL, 9.1 µmol, 1.1 equiv) were added and the mixture was stirred at room temperature for 6 hours. The reaction was monitored by TLC (CHCl 3 /MeOH/water 65:25:4, cinnamaldehyde staining). The crude was poured into 10 mL precooled MTBE placed in a 10 mL centrifugal tube (the reaction flask was rinsed with 3 × 50 µL of DMF and each rinsing solution was transferred to the MTBE tube). The tube was sealed, vortexed and placed in ice for 10 min. The tube was spun for 3 min at 4500 RPM in a precooled centrifuge. The supernatant was transferred to a 50 mL flask. The pellet was suspended again into 10 mL of MTBE by vortexing and sonication. The tube was placed on ice for 10 mins and the centrifugation was repeated. Then the pellet was dried in vacuo. The combined MTBE S14 phases were concentrated under reduced pressure and checked for remaining product by TLC and HPLC. The dried pellet was used in the next step without further purification (8.3 mg, 71% yield).
Cyclo[DKP-isoDGR]-Val-Ala-α-amanitin (10)
A solution of 4 (3.4 mg, 3.9 µmol, 1 equiv) in 150 µL of PBS was added to a solution of 13b (8.3 mg, 5.9 µmol, 1.5 equiv) in 150 µL of DMF at 0 °C. The pH was adjusted to 7.3-7.6 by adding small aliquots of aqueous NaOH (0.2 M) during the first hours of reaction (until a stable value was observed), then the reaction mixture was stirred overnight at room temperature. The solution was directly filtered into a 3 mL vial and purified by preparative HPLC (gradient: from 
4-Pentynoic acid NHS ester (17)
4-Pentynoic acid (10 mg, 0.100 mmol, 1 equiv) was dissolved in 2 mL of dry DCM under argon and cooled to 0 °C. EDC·HCl (23 mg, 0.120 mmol, 1.2 equiv) and NHS (14 mg, 0.120 mmol, 1.2 equiv) were sequentially added to the solution and the reaction mixture was stirred overnight at room temperature. The mixture was diluted in 20 mL of DCM and the organic phase was washed with water (3 × 7 mL), dried over MgSO 4 , filtrated and concentrated under reduced pressure to give the product as a yellowish oil that was used in next step without further modifications.
were added to a solution of compound 12b (5.0 mg, 4. 14- 6, 9, 100 µL (0.05 mmol, 1 equiv) of a 0.5 M solution of 14-azido-3,6,9,12-tetraoxatetradecanoic acid (~0.5 M in tert-butyl methyl ether) were diluted in 100 µL of dry DCM under argon and cooled to 0 °C. EDC·HCl (12,5 mg, 0.065 mmol, 1.3 equiv) and NHS (7.5 mg, 0.065 mmol, 1.3 equiv)
were sequentially added to the solution and the reaction mixture was stirred overnight at room temperature. The mixture was diluted in 10 mL of DCM and the organic phase was washed with water (3 × 3 mL), dried over MgSO 4 , filtrated and concentrated under reduced pressure to give the product as a transparent oil (18.2 mg, 97% yield). The crude product was used in the next step without further modifications. 
Cyclo[DKP-isoDGR]-PEG-4-Val-Ala-α-amanitin (11)
To a solution of 14 (2.9 mg, 2.3 µmol) in 1 mL of DMF at 0 °C, compound 16 (2.7 mg, 2,7 µmol) dissolved in 1 mL of water, sodium ascorbate (0.2 mg, 0.88 µmol) and CuSO 4 ·7 H 2 O (0.25 mg, 0.44 µmol) were sequentially added. The solution, which turned light yellow, was stirred overnight at room temperature until the color changed to light blue.
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